Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals [4] and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US.[5] It is under clinical evaluations in other countries.[3][6]
^
abSamson M, Pizzorno A, Abed Y, Boivin G (May 2013). "Influenza virus resistance to neuraminidase inhibitors". Antiviral Research. 98 (2): 174–185.
doi:
10.1016/j.antiviral.2013.03.014.
PMID23523943.